Floatz logo

Irinotecan

Mixed Lineage Acute Leukemia

Johns Hopkins All Children's HospitalSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Mixed Lineage Acute Leukemia cohort.

Asset / SponsorPhaseRating
Mitoxantrone
University of Washington
Phase 2BB
Vorinostat
Johns Hopkins All Children's Hospital
Phase 2B
Erwinia L-Asparaginase
St. Jude Children's Research Hospital
Phase 2CCC
Bortezomib
St. Jude Children's Research Hospital
Phase 2CCC
Osimertinib
Syndax Pharmaceuticals
Phase 1/2CCC

View all 10 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →